newsfilter
← Earnings
Earnings Releases·

LivaNova — Third Quarter 2026 Earnings Summary

LivaNova reported third-quarter 2026 revenue of $393.1 million, representing a 9.9% increase on a reported basis and a 10.0% increase on a constant-currency basis compared to the prior year. The company raised its full-year 2026 revenue growth guidance to a range of 9% to 10% and adjusted diluted earnings per share guidance to $4.40 to $4.50. Key operational milestones achieved include the launch of a dedicated oxygenator manufacturing line and the announcement of new CPT codes for its hypoglossal nerve stimulation therapy effective in 2028. Additionally, the company published 36-month results from the CORE-VNS study showing a 76% median reduction in seizure frequency for patients with drug-resistant epilepsy.

Company
LIVANOVA PLC
Sector
Healthcare
Industry
Medical Devices